机构：[1]Department of Respiratory Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China呼吸科首都医科大学宣武医院[2]Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA[3]Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China胸外科首都医科大学宣武医院
Circulating cell-free DNA (cfDNA) released by tumor cells, termed ctDNA, closely reflects the heterogeneity of primary cancers and their metastases. As a noninvasive, real-time monitoring biomarker, ctDNA is a promising tool for detecting driver gene mutations, assessing tumor burden and acquired resistance, and early diagnosis. However, isolation and enrichment of cfDNA is a big challenge due to the high degree of DNA fragmentation and its relatively low abundance in the bloodstream. This review aims to provide insights into the recent technological advances in acquisition of optimal quality cfDNA, the use of preservatives, isolation methods, processing timelines, and detection techniques. It also describes clinical applications of ctDNA in cancer patient management.
第一作者机构：[1]Department of Respiratory Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China[2]Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA
共同第一作者：
通讯作者：
通讯机构：[*1]Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 2340 Sutter St, N261, San Francisco, CA 94115, USA
推荐引用方式(GB/T 7714)：
Yi Chang,Bhairavi Tolani,Xiuhong Nie,et al.Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring[J].THERAPEUTICS AND CLINICAL RISK MANAGEMENT.2017,13:1363-1374.doi:10.2147/TCRM.S141991.
APA：
Yi Chang,Bhairavi Tolani,Xiuhong Nie,Xiuyi Zhi,Mu Hu&Biao He.(2017).Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring.THERAPEUTICS AND CLINICAL RISK MANAGEMENT,13,
MLA：
Yi Chang,et al."Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring".THERAPEUTICS AND CLINICAL RISK MANAGEMENT 13.(2017):1363-1374
